FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					$\overline{}$								1						
1. Name and Address of Reporting Person* REESE DAVID M					2. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
KEESE DAY ID W																			
-					- _{3.}	3. Date of Earliest Transaction (Month/Day/Year)								V Officer below)	(give title		Other (s	pecity	
(Last)	(F	irst)	(Middle)			05/02/2023								,			,		
ONE AMGEN CENTER DRIVE						05/02/2025								EVP, Research and Development					
					_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)													- 1	Line) X Form filed by One Reporting Person					
THOUS	AND												- -	Y Form fi	led by One	Repor	rting Persoi	י [
	AND													Form filed by More than One Reporting					
OAKS														Person					
(City)	(S	tate)	(Zip)		_ R	Rule 10b5-1(c) Transaction Indication													
					-1	Cheal this houts indicate that a house discuss and a constant in a contrast in the site of													
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisf the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										to satisfy									
		Tal	ble I - No	n-Der	ivativ	e Se	curitie	s Ac	quired,	Dis	posed o	f, or Ber	neficiall	y Owned					
1 Title of 9	Security (Ins	tr 3)		2. Tran	saction	1	2A. Deeme	ed be	3.		4. Securitie	es Acquired	d (A) or	5. Amou	nt of	6. Ownership	nership	7. Nature of	
1. 1166 01 0	occurry (ma	u. 0)		Date		Execution			Transaction Disposed (Of (D) (Instr. 3, 4 and 5)) Securitie	Securities		Direct	Indirect		
				(Month	/Day/Ye	ay/Year) if any (Month/Day/Year		u/Voor)	ar) Code (Instr. 8)				Beneficially Owned Following			Beneficial Ownership			
				l				y/ ieai j				_	1	Reported		(1) (11150. 4)		(Instr. 4)	
								Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)					
Common Stock 05				05/0)2/202	2/2023			A		3,814(1)) A	\$0	55,527			D		
Common Stock 05/0			03/202	/2023			F		819	D	\$235.9	7 54,70)8(2)(3)		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
				(e.g.,	puts	, call	s, warr	ants	, option	ıs, c	onvertib	ole secu	rities)						
1. Title of	2.	3. Transaction	3A. Deeme	d I	4.		5. Numb	ner	6. Date Exe	ercisa	able and	7. Title an	d Amount	8. Price of	9. Numbe	r of	10.	11. Nature	
Derivative Conversion Date Execution Date							n of E r. Derivative (Expiration Date of Securities (Month/Day/Year) Underlying			ies	Derivative	derivative		Ownership	of Indirect		
Security or Exercise (Month/Day/Year) if any						Instr.						g Coouritus	Security (Instr. 5)	Securities Beneficially			Beneficial		
(instr. 3)	(Instr. 3) Price of Month/Day/Year) 8						Securities Acquired				Derivative Sec (Instr. 3 and 4)				Owned				
	Security						(A) or					(,	l	Following	ollowing (I) ((I) (Instr. 4)		
							Disposed							Reported Transaction(s)			1		
							of (D) (Instr. 3, 4 and 5)								(Instr. 4)	on(s)			
					+					1 1									
													Amount or					1	
								l I.	D-4-		F		Number					1	
					Code	v	(A)		Date Exercisabl		Expiration Date	Title	of Shares						
Nqso (Right to	\$235.97	05/02/2023			A		32,250		05/02/2025	(4)	05/02/2033	Common	32,250	\$0	32,25		D		
Buy)	Ψ <i>Δ.33.71</i>	03/02/2023			A		32,230		03/02/2023	"	0310212033	Stock	32,230	"	32,23	~	D		

Explanation of Responses:

- 1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.
- 2. These shares include the following RSUs granted under the Company's equity plans: 2,325 RSUs which will vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,685 RSUs which will vest in installments of 1,325 on 3/5/2025, and one installment of 1,325 on 3/5/2025; 3,897 RSUs which will vest in two installments of 1,286 on 3/5/2025, and one installment of 1,325 on 3/5/2025; and 3,814 RSUs which will vest in installments of 1,286 on 3/5/2025, and one installment of 1,325 on 3/5/2025; and 3,814 RSUs which will vest in installments of 1,286 on 3/5/2025, 3,897 RSUs which will vest in installments of 3,250 on 3/5/2025, and one installment of 3,250 on 3/5/2025, 3,897 RSUs which will vest in installments of 3,250 on 3/5/2025, and one installment of 3,250 on 3/5/2025, 3,250 on 3/5/2025, and 3,250 on 3/5/2025, and one installment of 3/5/2025, and one install
- 3. These shares include 528 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount

/s/ David M. Reese

05/03/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.